Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of MK0773 in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 0773 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 18 Nov 2009 New trial record